#USA #Los Angeles #Securities Law #REGENXBIO #RGNX

Overview of the Class Action Lawsuit

On April 14, 2026, the DJS Law Group reminded shareholders about a class action lawsuit filed against Regenxbio Inc. (NASDAQ: RGNX). The lawsuit alleges violations of the Securities Exchange Act of 1934, particularly sections 10(b) and 20(a), as well as Rule 10b-5 enforced by the U.S. Securities and Exchange Commission (SEC). Investors who purchased shares of Regenxbio within the specified period may have the opportunity to join this legal action.

Class Period and Allegations

The class action covers a time frame from February 9, 2022, to January 27, 2026. During this period, Regenxbio made positive announcements regarding its RGX-111 product candidate, asserting its safety and effectiveness. However, the company is accused of concealing significant negative information regarding the product's safety profile from the investors.

The legal trouble began when the U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-111 due to alarming findings that a trial participant had developed a tumor. This incident raised serious questions about the trustworthiness of Regenxbio's public statements, which have now been classified as materially misleading and false throughout the class period.

Impact on Shareholders

The implications of this lawsuit are substantial for shareholders who may have suffered financial losses as a result of Regenxbio's statements. The DJS Law Group emphasizes that shareholders are encouraged to reach out to them to discuss potential participation in the case, stressing that one does not need to be appointed as a lead plaintiff to seek recovery. As the case develops, the opportunity for investors to regain their losses becomes a focal point for those affected.

DJS Law Group’s Role

The DJS Law Group prides itself on being an advocate for investors, specializing in securities class actions and corporate governance litigation. The firm aims to pursue aggressive legal strategies with a focus on enhancing investor returns. Their experience includes a strong background in handling claims that are valuable assets for their clients, which consist of some of the largest hedge funds and alternative asset managers globally.

This lawsuit against Regenxbio serves as a critical case for all investors to understand their rights and options when their investments may have been jeopardized by corporate misconduct. Due to the growing trend of litigation in the securities sector, it is increasingly essential for investors to remain vigilant and informed about their investments, especially in cases where corporate claims are put into question.

Conclusion

The class action lawsuit against Regenxbio Inc. not only highlights the risks associated with investing in biopharmaceutical companies but also underscores the importance of corporate transparency. The outcomes of this lawsuit will likely impact the company’s reputation and the future of its product candidates. For shareholders concerned about the potential ramifications, joining this legal action could represent a critical step toward seeking justice and recovering losses. Interested individuals should contact the DJS Law Group for further information and guidance regarding participation in the lawsuit, as the deadline for joining is April 14, 2026.

By taking proactive measures and engaging with legal representatives, shareholders can navigate this complex situation and advocate for their rights in light of the allegations against Regenxbio.